Brazilian Registry of Bone Biopsy (REBRABO): design, data elements and methodology

• Published in: Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia Vol. 36; no. 3; p. 352
• Main Authors: de Oliveira, Rodrigo Bueno, Barreto, Fellype Carvalho, Custódio, Melani Ribeiro, Gueiros, José Edvanilson Barros, Neves, Carolina Lara, Karohl, Cristina, Sampaio, Elisa de Albuquerque, da Costa, Rackel Mota, Canziani, Maria Eugênia Fernandes, Moysés, Rosa Maria Afonso, de Carvalho, Aluízio Barbosa, Jorgetti, Vanda
• Format: Journal Article
• Language: English; Portuguese
• Published: Brazil 01-07-2014
• Subjects: Biopsy; Bone and Bones - pathology; Bone Diseases, Metabolic - etiology; Bone Diseases, Metabolic - pathology; Brazil; Humans; Kidney Failure, Chronic - complications; Records as Topic; Registries; Research Design
• ISSN: 2175-8239

Mineral bone disorder (MBD) is a common condition in chronic kidney disease (CKD) patients and causes significant morbidity and mortality. Data involving prevalence of alterations in bone histological patterns, impact of different treatments and its repercussion in outcomes, such as bone fractures, hospitalization, cardiovascular disease and mortality, are scarce. Data bank registry can be a valuable tool to understand epidemiological aspects of MBD CKD. The Brazilian Registry of Bone Biopsy (REBRABO) will be a national registry, coordinating by the Brazilian Society of Nephrology - Committee of MBD-CKD.
To describe REBRABO's design, elements of data and methodology.
Will be an online national observational and multicentric data registry divided in two phases (retrospective, 1st phase) and prospective (2nd phase), including information from bone tissue histomorphometric analysis and demographics, clinical and laboratorial data from CKD-MBD patients.
The REBRABO's first phase will explore data on demographics, clinical, laboratorial and bone histomorphometric analysis data from January/1986 to December/2013. The first RESULTS are expected in early 2015.
Studies in the field of CKD-MBD are needed, particularly those analyzing its prevalence, associations between demographic, clinical, histological parameters, and major outcomes. The REBRABO will be a unique retrospective and prospective research platform including bone biopsy data in CKD-MBD patients.